Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention / Stephen V. FARAONE in Journal of Child Psychology and Psychiatry, 60-2 (February 2019)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 60-2 (February 2019) . - p.133-150 Titre : Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention Type de document : texte imprimé Auteurs : Stephen V. FARAONE, Auteur ; Anthony L. ROSTAIN, Auteur ; Joseph BLADER, Auteur ; Betsy BUSCH, Auteur ; Ann C. CHILDRESS, Auteur ; Daniel F. CONNOR, Auteur ; Jeffrey H. NEWCORN, Auteur Article en page(s) : p.133-150 Langues : Anglais (eng) Mots-clés : Attention-deficit/hyperactivity disorder  comorbidity  deficient emotional self-regulation  emotional dysregulation  emotional impulsivity  irritability  rating scale Index. décimale : PER Périodiques Résumé : BACKGROUND: Because emotional symptoms are common in attention-deficit/hyperactivity disorder (ADHD) patients and associate with much morbidity, some consider it to be a core feature rather than an associated trait. Others argue that emotional symptoms are too nonspecific for use as diagnostic criteria. This debate has been difficult to resolve due, in part, to the many terms used to describe emotional symptoms in ADHD and to concerns about overlap with mood disorders. METHODS: We sought to clarify the nature of emotional symptoms in ADHD by reviewing conceptual and measurement issues and by examining the evidence base regarding specificity of such symptoms for ADHD. We reviewed the various terms used to define emotional symptoms in ADHD, clarify how these symptoms are demarcated from mood disorders, and assess the possibility that symptoms of emotional impulsivity and deficient emotional self-regulation should be considered as core symptoms. We addressed psychiatric comorbidities, the effects of ADHD treatments on associated emotional dysregulation, and the utility of current rating scales to assess emotional symptoms associated with ADHD. RESULTS: Emotional symptoms are common and persistent in youth and adults with ADHD. Although emotional symptoms are common in other psychiatric disorders, emotional impulsivity (EI), and deficient emotional self-regulation (DESR) may be sufficiently specific for ADHD to function as diagnostic criteria. CONCLUSIONS: Emotional symptoms in ADHD cause clinically significant impairments. Although there is a solid theoretical rationale for considering EI and DESR to be core symptoms of ADHD, there is no consensus about how to define these constructs sin a manner that would be specific to the disorder. An instrument to measure EI and DESR which demarcates them from irritability and other emotional symptoms could improve the accuracy of diagnostic criteria for ADHD. En ligne : http://dx.doi.org/10.1111/jcpp.12899 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=381 [article] Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention [texte imprimé] / Stephen V. FARAONE, Auteur ; Anthony L. ROSTAIN, Auteur ; Joseph BLADER, Auteur ; Betsy BUSCH, Auteur ; Ann C. CHILDRESS, Auteur ; Daniel F. CONNOR, Auteur ; Jeffrey H. NEWCORN, Auteur . - p.133-150. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 60-2 (February 2019) . - p.133-150 Mots-clés : Attention-deficit/hyperactivity disorder  comorbidity  deficient emotional self-regulation  emotional dysregulation  emotional impulsivity  irritability  rating scale Index. décimale : PER Périodiques Résumé : BACKGROUND: Because emotional symptoms are common in attention-deficit/hyperactivity disorder (ADHD) patients and associate with much morbidity, some consider it to be a core feature rather than an associated trait. Others argue that emotional symptoms are too nonspecific for use as diagnostic criteria. This debate has been difficult to resolve due, in part, to the many terms used to describe emotional symptoms in ADHD and to concerns about overlap with mood disorders. METHODS: We sought to clarify the nature of emotional symptoms in ADHD by reviewing conceptual and measurement issues and by examining the evidence base regarding specificity of such symptoms for ADHD. We reviewed the various terms used to define emotional symptoms in ADHD, clarify how these symptoms are demarcated from mood disorders, and assess the possibility that symptoms of emotional impulsivity and deficient emotional self-regulation should be considered as core symptoms. We addressed psychiatric comorbidities, the effects of ADHD treatments on associated emotional dysregulation, and the utility of current rating scales to assess emotional symptoms associated with ADHD. RESULTS: Emotional symptoms are common and persistent in youth and adults with ADHD. Although emotional symptoms are common in other psychiatric disorders, emotional impulsivity (EI), and deficient emotional self-regulation (DESR) may be sufficiently specific for ADHD to function as diagnostic criteria. CONCLUSIONS: Emotional symptoms in ADHD cause clinically significant impairments. Although there is a solid theoretical rationale for considering EI and DESR to be core symptoms of ADHD, there is no consensus about how to define these constructs sin a manner that would be specific to the disorder. An instrument to measure EI and DESR which demarcates them from irritability and other emotional symptoms could improve the accuracy of diagnostic criteria for ADHD. En ligne : http://dx.doi.org/10.1111/jcpp.12899 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=381

The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder / Paul HERSCU in Journal of Autism and Developmental Disorders, 50-9 (September 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-9 (September 2020) . - p.3233-3244 Titre : The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder Type de document : texte imprimé Auteurs : Paul HERSCU, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Michael F. SNAPE, Auteur ; Joel D. BREGMAN, Auteur ; Lawrence D. GINSBERG, Auteur ; Robert L. HENDREN, Auteur ; Alexander KOLEVZON, Auteur ; Raun D. MELMED, Auteur ; Mark MINTZ, Auteur ; Nancy J. MINSHEW, Auteur ; Linmarie SIKICH, Auteur ; Ashraf ATTALLA, Auteur ; Brian KING, Auteur ; Thomas OWLEY, Auteur ; Ann CHILDRESS, Auteur ; Harry CHUGANI, Auteur ; Jean A. FRAZIER, Auteur ; Charles CARTWRIGHT, Auteur ; Tanya K. MURPHY, Auteur Article en page(s) : p.3233-3244 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Repetitive behavior  Selective seretonin reuptake inhibitor Index. décimale : PER Périodiques Résumé : Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. There is limited evidence supporting its efficacy for repetitive behaviors (RRBs) in autistic spectrum disorder (ASD). We conducted a randomized controlled trial (RCT) of fluoxetine in 158 individuals with ASD (5-17 years). Following 14 treatment weeks (mean dose 11.8 mg/day), no significant differences were noted on the Children's Yale-Brown Obsessive Compulsive Scale; the proportion of responders was similar (fluoxetine: 36%; placebo: 41%). There were similar rates of AEs (e.g., insomnia, diarrhea, vomiting); high rates of activation were reported in both groups (fluoxetine: 42%; placebo: 45%). Overly cautious dosing/duration may have prevented attainment of a therapeutic level. Results are consistent with other SSRI RCTs treating RRBs in ASD.Trial Registration: clinicaltrials.gov Identifier: NCT00515320. En ligne : http://dx.doi.org/10.1007/s10803-019-04120-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430 [article] The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder [texte imprimé] / Paul HERSCU, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Michael F. SNAPE, Auteur ; Joel D. BREGMAN, Auteur ; Lawrence D. GINSBERG, Auteur ; Robert L. HENDREN, Auteur ; Alexander KOLEVZON, Auteur ; Raun D. MELMED, Auteur ; Mark MINTZ, Auteur ; Nancy J. MINSHEW, Auteur ; Linmarie SIKICH, Auteur ; Ashraf ATTALLA, Auteur ; Brian KING, Auteur ; Thomas OWLEY, Auteur ; Ann CHILDRESS, Auteur ; Harry CHUGANI, Auteur ; Jean A. FRAZIER, Auteur ; Charles CARTWRIGHT, Auteur ; Tanya K. MURPHY, Auteur . - p.3233-3244. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-9 (September 2020) . - p.3233-3244 Mots-clés : Autism spectrum disorder  Repetitive behavior  Selective seretonin reuptake inhibitor Index. décimale : PER Périodiques Résumé : Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. There is limited evidence supporting its efficacy for repetitive behaviors (RRBs) in autistic spectrum disorder (ASD). We conducted a randomized controlled trial (RCT) of fluoxetine in 158 individuals with ASD (5-17 years). Following 14 treatment weeks (mean dose 11.8 mg/day), no significant differences were noted on the Children's Yale-Brown Obsessive Compulsive Scale; the proportion of responders was similar (fluoxetine: 36%; placebo: 41%). There were similar rates of AEs (e.g., insomnia, diarrhea, vomiting); high rates of activation were reported in both groups (fluoxetine: 42%; placebo: 45%). Overly cautious dosing/duration may have prevented attainment of a therapeutic level. Results are consistent with other SSRI RCTs treating RRBs in ASD.Trial Registration: clinicaltrials.gov Identifier: NCT00515320. En ligne : http://dx.doi.org/10.1007/s10803-019-04120-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430

---

1 (1 - 2 / 2) Par page : 25 50 100 200